MedTrace Logo

Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease

NCT00677534 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2014-04-29

Study results available
· View outcomes & findings →

Summary

The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease

Conditions

  • End-Stage Renal Disease

Interventions

DRUG

Cholecalciferol

50,000 Units PO Twice weekly for 8 weeks

Sponsors & Collaborators

  • University of Kansas

    lead OTHER

Principal Investigators

  • Jason Stubbs, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677534 on ClinicalTrials.gov